BioSpace News Archive

Business

Zimmer Biomet Announces Quarterly Dividend for First Quarter of 2019

Zimmer Biomet Holdings, Inc., a global leader in musculoskeletal healthcare, announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the first quarter of 2019.

March 7, 2019
·
1 min read
Deals

Bristol-Myers Squibb Announces Dividend payable on May 1, 2019

The Board of Directors of Bristol-Myers Squibb Company declared a quarterly dividend of forty one cents per share on the $.10 par value Common Stock of the corporation.

March 7, 2019
·
1 min read
Deals

Quest Diagnostics Prices $500 Million of Senior Notes - March 7, 2019

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced the pricing of a public offering of $500 million aggregate principal amount of its 4.200% senior notes due 2029 under the Quest Diagnostics’ shelf registration statement.

March 7, 2019
·
2 min read
Genetown

Verastem Oncology Presents Further COPIKTRA™ (Duvelisib) Data at the 23rd Annual International Congress on Hematologic Malignancies

DUO™ Crossover Extension Study Demonstrates 77% ORR and Median PFS of 15 Months in Patients with Relapsed or Refractory CLL/SLL Who Had Experienced Disease Progression Following Ofatumumab Monotherapy; Achieves 80% ORR in Patients with 17p Deletion

March 7, 2019
·
28 min read
Deals

ResMed Acquires HB Healthcare to Help Millions of Koreans Living with Sleep Apnea, Other Respiratory Conditions

ResMed, a global leader in cloud-connected sleep and respiratory care devices in more than 120 countries, announced that is has completed the acquisition of HB Healthcare to help millions of South Koreans living with sleep apnea, chronic obstructive pulmonary disease and other respiratory conditions.

March 7, 2019
·
3 min read
Biotech Bay

Gilead Announces Data From Two Studies Supporting Further Development of GS-6207, a Novel, Investigational HIV-1 Capsid Inhibitor as a Component of Future Long-Acting HIV Therapies

Gilead Sciences, Inc. announced findings from two studies that support the further development of GS-6207, a novel, selective, first-in-class inhibitor of HIV-1 capsid function, for potential future use as part of long-acting HIV combination therapy.

March 7, 2019
·
4 min read
Drug Development

Forbius Announces First Patient Dosed in Phase 2a Squamous Cell Carcinoma of the Head and Neck (SCCHN) Trial of AVID100, a Novel Anti-EGFR ADC

Forbius announced that the first patient has been dosed in a Phase 2a squamous cell carcinoma of the head and neck (SCCHN) clinical trial.

March 7, 2019
·
2 min read